you are here:

Sharon Bio Medicine Ltd.

BSE: 532908 | NSE: SHARONBIO | Series: NA | ISIN: INE028B01029 | SECTOR: Pharmaceuticals

BSE Live

Mar 28, 15:40
3.21 0.00 (0.00%)
Volume
No Data Available
32,550
  • Prev. Close

    3.21

  • Open Price

    3.26

  • Bid Price (Qty.)

    3.10 (100)

  • Offer Price (Qty.)

    3.26 (1000)

Sharon Bio Medicine is not traded on BSE in the last 30 days

NSE Live

Mar 28, 15:31
3.30 0.00 (0.00%)
Volume
No Data Available
8,834
  • Prev. Close

    3.30

  • Open Price

    3.30

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

Sharon Bio Medicine is not traded on NSE in the last 30 days
Company History - Sharon Bio Medicine
1995: Current Mnagement took over and started manufacturing of Pharma
 

 intermediates
 
 1997: Started manufacturing API's - launched its first drug
 Trimetazidine di 

 hydrochloride
 
 2000: Came withpublic offering of 25% Shares. Issue was
 oversubscribed 

 by 3.85 times.
 
 2000: Set up a R&D block to out Process synthesis for API's & 

 Intermediates.
 
 Jan 2005: Hon, Finance Minister of India Mr.P.Chidambaram put our 

 company on the INDO NEXT at the BOMBAY STOCK EXCHANGE.
 
 Jan 2005: Company was awarded with the ISO 9001-2000 accreditation by
 

 BVQI - UKAS & BVQI - ANAB
 
 Mid 2005: Commissioning of a State of Art Formulation Unit for Oral
 Solid 

 Dosages was started, Estimated cost of the project over 8 m USD
 
 2006: Currently  one of the leading manufacturers of  Trimetazidine
 Di HCL 

 , Ketoconazole and Pantoprazole Sodium in the country,besides
 catering to 

 a widerange of drug intermedites for the Anti fungal & Anti Ulcer
 categories 

 to name a few.
 
 The services provided by the company are  contract research and 

 manufacturers, technology transfers and project consultancy.
 
 2009
 
 - Company name has been changed from Sharon Pharma Chem Ltd to Sharon
 Bio-Medicine Ltd                                      .
 
 2010
 
 - Sharon Bio-Medicine Ltd has appointed Mr. Drunal Shah and Mr.
 Harish Palecanda, as Directors of the Company, w.e.f. December 31,
 2009.
 
 2011
 
 - Sharon Bio-Medicine Ltd has signed Memorandum of Understanding on
 February 24, 2011 between Sharon Bio-Medicine Ltd. and The State -
 Joint Stock Concern Uzpharmsanoat.
 
 - Sharon Bio-Medicine Ltd Approval of Good Laboratory Practices by
 Ministry of Science & Technology, New Delhi for Toxicology Unit
 
 2012
 
 -  Sharon Bio-Medicine Ltd  Board recommends Dividend dividend @ Rs.
 1.80 per share subject to approval of shareholders at the Annual
 General Meeting.
 
 - Sharon Bio-Medicine Ltd  receives Rs 690 lakh subsidy from Ministry
 of Science & Technology
 
 2013
 
 - Sharon Bio-Medicine has setting up a Genotoxicity Laboratory at
 Taloja near Navi Mumbai.
 -Sharon has recommended dividend of Rs. 1.50/- per share.
 - Mr. Madhav Manohar has been appointed as Additional Director w.e.f.
 September 01, 2013.
 
 2014
 
 -Sharon has recommended dividend @18%.
 -Sharon Bio-Medicine bags GLP Certificate for Raigarh unit
 -Sharon Bio-Medicine has announces bonus in the ratio of 1:1
 -Sharon Bio-Medicine has splits its face value from Rs 10/- to 2/-
                                                  
 2015
 -Sharon Bio-Medicine Ltd have received the certification for the
 approval of Good Manufacturing Practices (GMP) for both, Capsules and
 Tablets from United Kingdom - Medical & Health Care Product Regulatory
 Agency (UKMHRA) for its expanded area of Formulation and Tablets unit
 -Sharon Bio-Medicine gets EIR from USFDA for Dehradun mfg unit